Interactive effects of oligofructose and obesity predisposition on gut hormones and microbiota in diet‐induced obese rats

Objective Oligofructose (OFS) is a prebiotic that reduces energy intake and fat mass via changes in gut satiety hormones and microbiota. The effects of OFS may vary depending on predisposition to obesity. The aim of this study was to examine the effect of OFS in diet‐induced obese (DIO) and diet‐res...

Full description

Saved in:
Bibliographic Details
Published inObesity (Silver Spring, Md.) Vol. 23; no. 4; pp. 769 - 778
Main Authors Cluny, Nina L., Eller, Lindsay K., Keenan, Catherine M., Reimer, Raylene A., Sharkey, Keith A.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.04.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective Oligofructose (OFS) is a prebiotic that reduces energy intake and fat mass via changes in gut satiety hormones and microbiota. The effects of OFS may vary depending on predisposition to obesity. The aim of this study was to examine the effect of OFS in diet‐induced obese (DIO) and diet‐resistant (DR) rats. Methods Adult, male DIO, and DR rats were randomized to: high‐fat/high‐sucrose (HFS) diet or HFS diet + 10% OFS for 6 weeks. Body composition, food intake, gut microbiota, plasma gut hormones, and cannabinoid CB1 receptor expression in the nodose ganglia were measured. Results OFS reduced body weight, energy intake, and fat mass in both phenotypes (P < 0.05). Select gut microbiota differed in DIO versus DR rats (P < 0.05), the differences being eliminated by OFS. OFS did not modify plasma ghrelin or CB1 expression in nodose ganglia, but plasma levels of GIP were reduced and PYY were elevated (P < 0.05) by OFS. Conclusions OFS was able to reduce body weight and adiposity in both prone and resistant obese phenotypes. OFS‐induced changes in gut microbiota profiles in DIO and DR rats, along with changes in gut hormone levels, likely contribute to the sustained lower body weights.
Bibliography:The study was funded by grants from Canadian Institutes of Health Research (to RAR [MOP 115076‐1] and KAS [OTG 88592 and MOP 38185]). KAS holds the Crohn's and Colitis Foundation of Canada Chair in Inflammatory Bowel Disease Research. NLC is an Alberta Innovates—Health Solutions (AI‐HS) fellow.
NLC, RAR, and KAS designed the studies; NLC, LKE, and CMK conducted the research; NLC, LKE, RAR, and KAS analyzed the data; all authors wrote and revised the article and agree to its submission.
Disclosure
Funding agencies
The authors declare no conflict of interest.
Author contributions
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1930-7381
1930-739X
DOI:10.1002/oby.21017